Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Leukocyte Immunoglobulin-Like Receptor (LILR)

Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101689

Synonyms

Historical Background

The leukocyte immunoglobulin (Ig)-like receptor (LILR) multigene family consists of two pseudogenes (LILRP1 and LILRP2) and 11 functional genes that encode five activating (LILRA1, LILRA2, LILRA4, LILRA5, and LILRA6), five inhibitory (LILRB1, LILRB2, LILRB3, LILRB4, and LILRB5), and one soluble (LILRA3) form. The LILR gene family was independently discovered by different investigators around the same time. Immunoglobulin-like transcripts 1 and 2 (ILT1 and ILT2), which correspond to LILRA2 and LILRB1, respectively, were identified as novel molecules of the immunoglobulin superfamily (IgSF) using IgSF-related PCR primers (Samaridis and Colonna 1997). The leukocyte immunoglobulin-like receptor (LIR-1), which corresponds to LILRB1, was identified as the receptor for the human cytomegalovirus (HCMV) UL18 gene product, an HLA class I mimic (Cosman et al. 1997). MIR-7 and MIR-10, which correspond to LILRB1 and LILRB2, respectively, were identified as gp49B-related molecules (Wagtmann et al. 1997). HM18, HM31/HM43, and HL9, which correspond to LILRB4, LILRA3, and LILRB3, respectively, were identified using a mouse gp49A probe (Arm et al. 1997). CD85 was originally defined at the 5th Workshop on Leukocyte Antigens in 1993 by two monoclonal antibodies, VMP55 and GHI/75, and was shown to correspond to ILT2, owing to the discovery of the LILR genes (Banham et al. 1999); thus, several names (i.e., ILT, LIR, MIR HM/HL, and CD85) have been assigned to this gene family. Although CD85 designations were proposed for this gene family during the 7th HLDA Workshop (Andre et al. 2001), the LILR nomenclature was approved for this gene family by the HUGO gene nomenclature committee (Gray et al. 2015); therefore, this LILR nomenclature is often used in the literature. All of the LILR genes were identified by characterizing their genomic organization (Wende et al. 2000; Wilson et al. 2000).

Genetic Diversity

The LILR family is encoded in the leukocyte receptor complex (LRC) on human chromosome 19q13.4, which contains a number of receptors related to IgSF, such as killer Ig-like receptors. The LRC-syntenic region on mouse chromosome 7 does not encode a direct homolog of the LILR family but, instead, encodes paired immunoglobulin-like receptors (PIR), which have been proposed to be the murine homolog of the LILR family because of its expression pattern, synteny with the LRC region, sequence, and function (Takai 2005). Different numbers of LILR genes are observed among individuals of the same species, indicating that LILR genes are rapidly evolving and are exhibiting greater intraspecies and interspecies differences; this suggests that selective pressures, such as microbial pathogens, could have driven the evolution and diversification of the LILR family (Hirayasu and Arase 2015).

The LILR gene cluster is separated into centromeric and telomeric clusters, which are transcribed in opposite directions, from telomere to centromere and from centromere to telomere, respectively (Fig. 1). The centromeric LILR gene cluster may be formed by inverse duplication of the ancestral telomeric LILR gene cluster. In the LILR gene cluster, a number of genetic polymorphisms have been detected. Nonsense mutations in LILRA3 have been detected in Northeast Asian populations, and these nonfunctional lineages may have been maintained for a long period of time, suggesting that balancing selection acted on this locus (Hirayasu et al. 2006). LILRA3 also exhibits a presence or absence variation owing to a large deletion that removes almost the entire gene; this is skewed toward a higher frequency in Northeast Asian populations (up to 84%) than in European (17%) and African (7%) populations (Hirayasu et al. 2008). LILRA3 is the most differentiated of all the copy-number-variable genes in the human genome, suggesting that the LILRA3 locus may be sensitive to the local environment that includes microorganisms. LILRA3 polymorphisms have been associated with plasma levels of high-density lipoprotein cholesterol (HDL-C), as well as multiple sclerosis (MS), Sjögren’s syndrome (SS), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and prostate cancer (Fig. 1). In addition, LILRA6 also exhibits variation in copy number; however, unlike LILRA3, the LILRA6 copy number observed in an individual ranges from one to six, which is explained by the deletion or duplication of this gene (Bashirova et al. 2014; Lopez-Alvarez et al. 2014), and the LILRA6 copy-number variation is a possible risk factor for atopic dermatitis (AD). A recent study demonstrated that LILRA3 and LILRA6 copy numbers per haplotype vary from 0 to 2 and from 0 to 4, respectively (Lopez-Alvarez et al. 2016). LILRB1 shows a number of SNPs in the promoter and coding regions affecting its cell surface expression, which is significantly associated with RA susceptibility in HLA-DRB1 shared epitope negative patients. LILRB2 SNPs commonly found in Northeast Asian populations are significantly associated with low cell surface expression in monocytes. LILRB3 is highly polymorphic and displays a high ratio of nonsynonymous to synonymous substitutions, consistent with positive selection (Lopez-Alvarez et al. 2014); in addition, the LILRB3 region may be associated with susceptibility to Takayasu’s arteritis (TA). This LILRB3 polymorphism is associated with increased expression of the pseudogene LILRP1, which is evolutionarily related to the LILRB3 gene. LILRP1 transcripts may regulate LILR expression by competing for LILR-specific microRNA. LILRB4 shows several nonsynonymous SNPs associated with cell surface expression on dendritic cells (DCs) in SLE patients, and LILRB5 has a missense variant associated with serum creatine kinase (CK) and lactate dehydrogenase (LDH), as revealed by a genome-wide association study. LILRA2 has a unique functional SNP that disrupts the splice-acceptor site of intron 6, resulting in the generation of an alternative splicing isoform that lacks three amino acids in the stalk region, which is significantly associated with SLE and microscopic polyangiitis.
Leukocyte Immunoglobulin-Like Receptor (LILR), Fig. 1

Genomic organization of the LILR genes. The LILR multigenes are located on the long arm of human chromosome 19q13.4. Blue-filled and gray-filled boxes represent functional genes and pseudogenes, respectively, although some genes that lie in this region are omitted. Horizontal and vertical arrows indicate the transcriptional direction and the positions of suggested genetic associations, respectively. AD, atopic dermatitis; CK, creatine kinase; HDL, high-density lipoprotein cholesterol; LDH, lactate dehydrogenase; MPA, microscopic polyangiitis; MS, multiple sclerosis; PC, prostate cancer; RA, rheumatoid arthritis; SS, Sjögren’s syndrome; SLE, systemic lupus erythematosus; TA, Takayasu’s arteritis

Function in Response to Endogenous Ligands

Inhibitory LILRBs possess two (LILRB4) or four (LILRB1, LILRB2, LILRB3, and LILRB5) C2-type Ig-like domains and a long cytoplasmic tail with two (LILRB5), three (LILRB2 and LILRB4), and four (LILRB1 and LILRB3) immunoreceptor tyrosine-based inhibition motifs (ITIMs; Fig. 2). In contrast, activating LILRAs have two (LILRA5) or four (LILRA1, LILRA2, LILRA4, and LILRA6) C2-type Ig-like domains with short cytoplasmic tails and associate with the FcRγ chain containing immunoreceptor tyrosine-based activation motifs (ITAMs; Fig. 2). LILRA3 has four Ig-like domains without transmembrane and cytoplasmic domains, resulting in a soluble form (Fig. 2); however, the soluble forms of all LILRs without transmembrane and cytoplasmic regions are generated by alternative splicing.
Leukocyte Immunoglobulin-Like Receptor (LILR), Fig. 2

LILR structure and expression. Five inhibitory LILRBs have two or four Ig-like domains in the extracellular region and two, three, or four ITIMs (white box) in the intracellular region. Five activating LILRAs have two or four Ig-like domains in the extracellular region and associate with ITAM (red box)-containing FcRγ (purple molecule) in the transmembrane region. LILRA3, the only soluble form, has four Ig-like domains in the extracellular region and no transmembrane or cytoplasmic regions. B, B cells; DC, dendritic cells; G, granulocyte; HSC, hematopoietic stem cells; Mac, macrophage; Mast, mast cells; Mo, monocyte; NK, natural killer cells; PC, plasmablast cells; pDC, plasmacytoid DC; PMN, polymorphonuclear neutrophil; T, T cells

The signaling molecules downstream of LILRs remain poorly characterized. Inhibitory LILRBs signal through their ITIMs within cytoplasmic domains, and Lck, SHP-1, and Csk contribute to the LILRB1 signaling pathway. In contrast, activating LILRAs signal through ITAMs within the FcRγ chain and Syk kinase is associated with LILRA2 and LILRA4. Structurally, LILRs were initially categorized into group-1 members (LILRB1, LILRB2, LILRA1, LILRA2, and LILRA3) that recognize HLA class I molecules and group-2 members (LILRB3, LILRB4, LILRB5, LILRA4, LILRA5, and LILRA6) that do not recognize HLA class I molecules, according to the LILRB1 residues that interact with its ligand HLA class I molecules; however, this structural categorization is inconsistent with their ligand recognition. LILRA2, a group-1 LILR member, does not bind to HLA class I molecules, although LILRA2 shows >80% sequence identity with LILRB1, and, LILRB5, a group-2 LILR member, binds to HLA class I heavy chains. Crystal structures are available for LILRB1, LILRB2, LILRB4, LILRA2, LILRA3, and LILRA5. The LILR family has unique expression patterns across different tissues, such as hematopoietic lineages and neurons (Fig. 2), and each LILR recognizes different ligands. Thus, LILRs affect diverse biological functions (Burshtyn and Morcos 2016). The following are the functions of individual LILRs and endogenous ligands.

LILRB1. LILRB1 recognizes a broad range of HLA class I molecules but does not recognize β2 microglobulin (β2m)-free forms of HLA class I molecules. Recognition is dependent upon the nonpolymorphic α3 domain of HLA class I heavy chain and β2m and is competitive with CD8, suggesting that LILRB1 modulates CD8-positive T cells by blocking CD8 binding. LILRB1 is expressed on B cells, myeloid cells, and subsets of T and NK cells. HLA class I molecules are important ligands of LILRB1 that help to avoid killing self-cells that expresses self-HLA class I molecules and to eliminate nonself or missing self-cells that do not express self HLA class I molecules (Colonna et al. 1997; Fig. 3).
Leukocyte Immunoglobulin-Like Receptor (LILR), Fig. 3

A proposed model of LILR inhibition exemplified by LILRB1. Immune cells, such as NK cells, transmit inhibitory signaling and do not attack normal cells by recognizing HLA class I molecules on normal cells via LILRB1. However, NK cells kill target cells, such as virus-infected and tumor cells that lack HLA class I molecules (missing self) owing to a loss of inhibitory signaling via LILRB1 (missing self-response). To evade the host immune system, some viruses or bacteria express LILRB1 ligands (mimics) to directly inhibit immune cells

LILRB2. In contrast to LILRB1, LILRB2 recognizes β2m-free forms of HLA class I molecules as well as heavy chain dimers, including HLA-B27 and HLA-G, more strongly than classical HLA class I molecules. Furthermore, LILRB2 binding to HLA class I molecules is affected by peptide antigens presented by HLA class I molecules. LILRB2 also recognizes an HLA-like protein, CD1d, on the cell surface and in the endosomal and lysosomal compartments to block the loading of lipid antigens onto CD1d. Furthermore, LILRB2 recognizes non-HLA ligands, such as angiopoietin-like proteins (ANGPTL), the oligomeric forms of β-amyloid, Nogo66, MAG, and OMgp. LILRB2 is expressed on myeloid cells, hematopoietic stem cells (HSCs), and neuron but not T, B, or NK cells. The murine homolog of LILRB2 appears to be PIR-B, the only inhibitory form of the murine PIR family with respect to expression pattern, ligands, and function; therefore, PIR-B-deficient mice are often used to analyze LILRB2 function. LILRB2 inhibitory functions are dependent on the ligands and cell types. In immune regulation, LILRB2 is involved in the functional inhibition of myelomonocytic cells by recognizing HLA class I molecules. In cell differentiation, ANGPTLs inhibit differentiation and support the expansion of HSCs via LILRB2. In neuronal function, myelin inhibitors, including Nogo66, MAG, and OMgp, are associated with LILRB2 and regulate axon regeneration. In addition, the oligomeric forms of β-amyloid trigger Alzheimer’s disease via LILRB2.

LILRB3. LILRB3 recognizes cytokeratin-8-associated ligands on necrotic glandular epithelial cells, although the function of LILRB3 remains unclear. LILRB3 is expressed mainly on monocytes, DCs, and granulocytes. Allogeneic antibodies against LILRB3 have been detected in HSC transplant recipients and may affect the graft-versus-leukemia effect against LILRB3-expressing leukemic cells. Because LILRB3 is highly polymorphic, the large difference between the amino acid sequences of LILRB3 in donors and recipients might lead to alloantibody production.

LILRB4. LILRB4 is expressed on monocytes, macrophages, DCs, and plasmablast cells. Upregulation of LILRB4 along with LILRB2 is associated with the tolerization of antigen-presenting cells, but its ligands and functions remain unknown.

LILRB5. LILRB5 is expressed on monocytes, DCs, mast cell granules, and T cells and recognizes HLA class I heavy chains, although its function is poorly characterized.

LILRA1. LILRA1 is expressed on monocytes and B cells. LILRA1 has been reported to bind preferentially to the free heavy chains of HLA-B27 and HLA-C but with lower affinity than LILRB1 and LILRB2. Although HLA-B27 was the first ligand identified in the activating LILRAs, it is not known why the activating receptor LILRA1 recognizes HLA class I molecules.

LILRA2. LILRA2 is expressed on monocytes, macrophages, DCs, granulocytes, and minor subsets of T and NK cells. Although its endogenous ligands remain unknown, LILRA2 detects dangerous immunological situations in which antibodies are destroyed by pathogens (as described below).

LILRA3. LILRA3 is the only soluble form of LILR secreted by monocytes, B cells, and subsets of T cells and is not detected on the cell surface. LILRA3 binds to HLA class I molecules with lower affinities than LILRB1 and LILRB2, although the function of these interactions remains unknown. LILRA3 is a high affinity receptor for Nogo66 and promotes synapse formation by competitive blocking Nogo66-mediated inhibition of neurite outgrowth by LILRB2.

LILRA4. LILRA4 expression is uniquely and selectively expressed on plasmacytoid DCs (pDCs) but not on monocytes, T, B, or NK cells. LILRA4 recognizes BST2 on multiple types of cancer cells as a ligand and suppresses pDC activation. Although the exact mechanism of this inhibitory function of LILRA4 through ITAM-containing FcRγ remains unknown, ligand-binding avidity may be partially involved in the function of this inhibitory ITAM. LILRA4 may suppress pDC by recognizing BST2 induced by type I interferons from neighboring cells in a negative-feedback manner.

LILRA5. LILRA5 is expressed on monocytes and neutrophils but its ligands and function are unknown. The crystal structure of LILRA5 was first reported for the group-2 LILR members. LILRA5 shows large changes in structural conformation and charge distribution related to the HLA class I binding sites of LILRB1 and LILRB2, consistent with the observation that LILRA5 does not bind to HLA class I molecules.

LILRA6. LILRA6 expression has been confirmed at the mRNA level in monocytes but not in T, B, or NK cells, and its function remains unclear.

Function in Response to Exogenous Ligands

LILRB1 was identified as a receptor for the HCMV gene product UL18, the first ligand identified in the LILR family (Cosman et al. 1997). UL18 is a glycoprotein homologous to the MHC class I molecules and associates with β2m and endogenous peptides. UL18 binding to LILRB1 was initially thought to be an immune evasion strategy for HCMV to inhibit the immune response through LILRB1 inhibitory signaling (Borges and Cosman 2000; Fig. 3); however, the function of UL18 has remained controversial because UL18 inhibits LILRB1-positive NK cells but activates LILRB1-negative NK cells, as well as LILRB1-positive and CD8-positive T cells. LILRB1 is also exploited by the dengue virus to prevent FcγR-dependent transcription of IFN-stimulated genes and escape from an antiviral response using mimics of the LILRB1 ligand. Bacteria, such as Staphylococcus aureus and Escherichia coli, are also recognized by LILRB1. Mice deficient in PIR-B, a putative LILRB1 counterpart, show resistance to S. aureus, suggesting that LILRB1 may be exploited by bacteria for immune evasion. LILRB2 is also exploited by HIV-1 as HIV-1 mutations at peptides on HLA class I molecules enhance binding to LILRB2 and lead to the functional inhibition of myelomonocytic cells. LILRB3 binds to S. aureus but not to E. coli, although these functional outcomes are unknown.

LILRA2 is a unique activating LILR that detects microbial immune evasion (Hirayasu et al. 2016; Fig. 4). Various microbial pathogens, such as Legionella pneumophila, Candida albicans, and S. aureus, have acquired proteases to disrupt antibodies to escape from antibody recognition; however, LILRA2 recognizes this microbially cleaved antibody to defend against pathogens. Therefore, activating LILRAs seem to play an important role in host defense against microbial pathogens. Moreover, mean cell numbers of LILRA2-expressing cells in synovial tissue are correlated with RA severity, suggesting that the interaction between LILRA2 and cleaved immunoglobulins may be involved in RA pathogenesis.
Leukocyte Immunoglobulin-Like Receptor (LILR), Fig. 4

A proposed model of LILR activation exemplified by LILRA2. Some microbial pathogens cleave immunoglobulins (Ig) using proteases to escape from antibody recognition. However, LILRA2 defends against this microbial evasion by recognizing the microbially cleaved immunoglobulins, resulting in the elimination of intracellular pathogens in addition to the induction of cytokines and reactive oxygen species (ROS). Mac, macrophage; Mo, monocyte; PMN, polymorphonuclear neutrophil

Summary

The LILR family was first discovered in 1997. Since then, a number of studies have suggested a diverse array of LILR functions, including missing self-response, immune tolerance, cell differentiation, targets of microbial immune evasion, antimicrobial response, and nervous system plasticity. In addition, the LILR family is of particular interest for understanding genome evolution because the LILR gene cluster evolved under positive and balancing selection; however, their physiological functions remain largely unknown. The function of LILRB1, which ligands were identified for the first time in the LILR family, remains unknown and controversial because of a lack of animal models to assess physiological roles of specific LILRs. Transgenic animals or nonhuman primate models are necessary to further understand the LILR family. Alternatively, genetic association studies of LILR genes may shed light on the physiological basis of LILR functions in humans, as genome-wide association studies have identified LILR variants that are associated with unexpected phenotypes, such as HDL-C, CK, and LDH. Therefore, the LILR family offers great potential to understand human molecular biology and evolution.

References

  1. Andre P, Biassoni R, Colonna M, Cosman D, Lanier LL, Long EO, Lopez-Botet M, Moretta A, Moretta L, Parham P, Trowsdale J, Vivier E, Wagtmann N, Wilson MJ. New nomenclature for MHC receptors. Nat Immunol. 2001;2(8):661.PubMedCrossRefGoogle Scholar
  2. Arm JP, Nwankwo C, Austen KF. Molecular identification of a novel family of human Ig superfamily members that possess immunoreceptor tyrosine-based inhibition motifs and homology to the mouse gp49B1 inhibitory receptor. J Immunol. 1997;159(5):2342–9.PubMedGoogle Scholar
  3. Banham AH, Colonna M, Cella M, Micklem KJ, Pulford K, Willis AC, Mason DY. Identification of the CD85 antigen as ILT2, an inhibitory MHC class I receptor of the immunoglobulin superfamily. J Leukoc Biol. 1999;65(6):841–5.PubMedCrossRefGoogle Scholar
  4. Bashirova AA, Apps R, Vince N, Mochalova Y, Yu XG, Carrington M. Diversity of the human LILRB3/A6 locus encoding a myeloid inhibitory and activating receptor pair. Immunogenetics. 2014;66(1):1–8.PubMedCrossRefGoogle Scholar
  5. Borges L, Cosman D. LIRs/ILTs/MIRs, inhibitory and stimulatory Ig-superfamily receptors expressed in myeloid and lymphoid cells. Cytokine Growth Factor Rev. 2000;11(3):209–17.PubMedCrossRefGoogle Scholar
  6. Burshtyn DN, Morcos C. The expanding spectrum of ligands for leukocyte Ig-like receptors. J Immunol. 2016;196(3):947–55.PubMedCrossRefGoogle Scholar
  7. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, Lopez-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med. 1997;186(11):1809–18.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Cosman D, Fanger N, Borges L, Kubin M, Chin W, Peterson L, Hsu ML. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity. 1997;7(2):273–82.PubMedCrossRefGoogle Scholar
  9. Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Genenames.org: the HGNC resources in 2015. Nucleic Acids Res. 2015;43(Database issue):D1079–85.PubMedCrossRefGoogle Scholar
  10. Hirayasu K, Arase H. Functional and genetic diversity of leukocyte immunoglobulin-like receptor and implication for disease associations. J Hum Genet. 2015;60(11):703–8.PubMedCrossRefGoogle Scholar
  11. Hirayasu K, Ohashi J, Kashiwase K, Takanashi M, Satake M, Tokunaga K, Yabe T. Long-term persistence of both functional and non-functional alleles at the leukocyte immunoglobulin-like receptor A3 (LILRA3) locus suggests balancing selection. Hum Genet. 2006;119(4):436–43.PubMedCrossRefGoogle Scholar
  12. Hirayasu K, Ohashi J, Tanaka H, Kashiwase K, Ogawa A, Takanashi M, Satake M, Jia GJ, Chimge NO, Sideltseva EW, Tokunaga K, Yabe T. Evidence for natural selection on leukocyte immunoglobulin-like receptors for HLA class I in Northeast Asians. Am J Hum Genet. 2008;82(5):1075–83.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Hirayasu K, Saito F, Suenaga T, Shida K, Arase N, Oikawa K, Yamaoka T, Murota H, Chibana H, Nakagawa I, Kubori T, Nagai H, Nakamaru Y, Katayama I, Colonna M, Arase H. Microbially cleaved immunoglobulins are sensed by the innate immune receptor LILRA2. Nat Microbiol. 2016;1(6):16054.PubMedCrossRefGoogle Scholar
  14. Lopez-Alvarez MR, Jiang W, Jones DC, Jayaraman J, Johnson C, Cookson WO, Moffatt MF, Trowsdale J, Traherne JA. LILRA6 copy number variation correlates with susceptibility to atopic dermatitis. Immunogenetics. 2016;68(9):743–7.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Lopez-Alvarez MR, Jones DC, Jiang W, Traherne JA, Trowsdale J. Copy number and nucleotide variation of the LILR family of myelomonocytic cell activating and inhibitory receptors. Immunogenetics. 2014;66(2):73–83.PubMedCrossRefGoogle Scholar
  16. Samaridis J, Colonna M. Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways. Eur J Immunol. 1997;27(3):660–5.PubMedCrossRefGoogle Scholar
  17. Takai T. Paired immunoglobulin-like receptors and their MHC class I recognition. Immunology. 2005;115(4):433–40.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Wagtmann N, Rojo S, Eichler E, Mohrenweiser H, Long EO. A new human gene complex encoding the killer cell inhibitory receptors and related monocyte/macrophage receptors. Curr Biol. 1997;7(8):615–8.PubMedCrossRefGoogle Scholar
  19. Wende H, Volz A, Ziegler A. Extensive gene duplications and a large inversion characterize the human leukocyte receptor cluster. Immunogenetics. 2000;51(8–9):703–13.PubMedCrossRefGoogle Scholar
  20. Wilson MJ, Torkar M, Haude A, Milne S, Jones T, Sheer D, Beck S, Trowsdale J. Plasticity in the organization and sequences of human KIR/ILT gene families. Proc Natl Acad Sci U S A. 2000;97(9):4778–83.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Laboratory of Immunochemistry, WPI Immunology Frontier Research CenterOsaka UniversityOsakaJapan
  2. 2.Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka UniversityOsakaJapan